U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Jimmy Lai Convicted Under Hong Kong National Security Law in Landmark Case 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Colombia’s Clan del Golfo Peace Talks Signal Mandatory Prison Sentences for Top Leaders 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Chemours, Dupont De Nemours, and Corteva have announced a $110 million settlement with the U.S. state of Ohio to resolve claims linked to toxic "forever chemicals." This agreement aims to address concerns surrounding per- and polyfluoroalkyl substances (PFAS).
Nasdaq reported that the chemical has been associated with various health risks. The settlement covers costs related to the release of PFAS from the companies' facilities, including the Washington Works site situated along the Ohio-West Virginia border, as per Reuters.
Responsibility Distribution for Settlement Costs
According to the agreement, Chemours, a spin-off of DuPont, will bear 50% of the settlement costs, while DuPont will contribute approximately $39 million. Corteva, on the other hand, is expected to cover the remaining expenses. The resolution brings an end to Ohio's claims concerning the release of PFAS, affording the state an opportunity to address this issue comprehensively.
The resolution of the Ohio settlement emphasizes the importance of addressing the wide-reaching implications of PFAS contamination.
Notably, the settlement between the companies and Ohio has triggered a contingency provision outlined in Delaware's 2021 PFAS settlement with the same entities.
This provision requires an additional payment of $25 million to the state of Delaware and the original $50 million settlement if a similar agreement is reached within eight years with another state, amounting to over $50 million. This provision underlines the accountability held by chemical manufacturers in addressing the concerns associated with PFAS contamination.
Legal Battles Surrounding PFAS
Chemical manufacturers have faced numerous lawsuits in recent years regarding alleged PFAS contamination. In a significant ruling, a U.S. appeals court rejected a lower court's decision that would have allowed approximately 11.8 million Ohio residents to sue 10 PFAS manufacturers as a collective group. The legal landscape demonstrates the complexity surrounding PFAS-related claims and the efforts to hold responsible parties accountable for their actions.
In June, 3M agreed to a $10.3 billion settlement to address hundreds of claims alleging the company had contaminated public drinking water with PFAS. Similarly, Chemours, DuPont, and Corteva reached a separate settlement with U.S. water providers, amounting to $1.19 billion.
These settlements underscore the growing recognition within the industry regarding the need to address PFAS-related concerns and the responsibility manufacturers bear in ensuring the safety of their products and practices.
Photo: DuPont Newsroom
